DK1776137T3 - Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2 - Google Patents

Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2 Download PDF

Info

Publication number
DK1776137T3
DK1776137T3 DK05767871.6T DK05767871T DK1776137T3 DK 1776137 T3 DK1776137 T3 DK 1776137T3 DK 05767871 T DK05767871 T DK 05767871T DK 1776137 T3 DK1776137 T3 DK 1776137T3
Authority
DK
Denmark
Prior art keywords
disorders
botulinum toxin
type
botulinum
toxin type
Prior art date
Application number
DK05767871.6T
Other languages
English (en)
Inventor
Naveed Panjwani
Paul Webb
Andy Pickett
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35063257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1776137(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417367A external-priority patent/GB2416692A/en
Priority claimed from GB0421290A external-priority patent/GB2418359A/en
Priority claimed from GB0421288A external-priority patent/GB2418358A/en
Priority claimed from GB0423952A external-priority patent/GB2419526A/en
Priority claimed from GB0423953A external-priority patent/GB2419527A/en
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Application granted granted Critical
Publication of DK1776137T3 publication Critical patent/DK1776137T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)

Claims (14)

1
1. Botulinumtoksin type A2 til anvendelse ved behandling, forudsat at botuli-numtoksinet A2 ikke anvendes til behandling af hirsutisme eller hypertricho- 5 se.
2. Botulinumtoksin type A2 til anvendelse ved behandling ifølge krav 1, hvor botulinumtoksinet type A2 er botulinumneurotoksinkompleks type A2 eller botulinumneurotoksin type A2 med høj renhed, og hvor botulinumtoksinet 10 type A2 er en del af en fast eller flydende farmaceutisk sammensætning, der endvidere omfatter et overfladeaktivt stof, fortrinsvis et ikke-ionisk overfladeaktivt stof.
3. Botulinumtoksin type A2 til anvendelse ved behandling ifølge krav 2, hvor 15 den faste eller flydende farmaceutiske sammensætning endvidere omfatter et krystallinsk stof, fortrinsvis natriumchlorid.
4. Botulinumtoksin type A2 til anvendelse ved behandling ifølge krav 2 eller 3, hvor den faste eller flydende farmaceutiske sammensætning endvidere 20 omfatter en buffer til at holde en pH-værdi på mellem 5,5 og 7,5, fortrinsvis på mellem 5,8 og 7,0.
5. Botulinumtoksin type A2 til anvendelse ved behandling ifølge et af kravene 2 til 4, hvor den faste eller flydende farmaceutiske sammensætning endvide- 25 re omfatter et disaccharid, fortrinsvis valgt fra gruppen bestående af saccha rose, trehalose, laktose og mannitol.
6. Botulinumtoksin type A2 til anvendelse ved behandling ifølge et af kravene 2 til 5, hvor det overfladeaktive stof er ikke-ionisk overfladeaktivt stof, der er 30 valgt fra gruppen bestående af polysorbater og blokcopolymerer.
7. Botulinumtoksin type A2 til anvendelse ved behandling ifølge krav 6, hvor det ikke-ioniske overfladeaktive stof er valgt fra gruppen bestående af polysorbater med en gennemsnitlig polymeriseringsgrad i området fra 20 til 100 35 monomerenheder og poloxamere. 2
8. Botulinumtoksin type A2 til anvendelse ved behandling ifølge et af kravene 2 til 7, hvor det ikke-ioniske overfladeaktive stof er polysorbat 80.
9. Botulinumtoksin type A2 ifølge et af kravene 1 til 8 til anvendelse ved be- 5 handling af en sygdom, en lidelse eller et syndrom, der er udvalgt fra oftalmo- logiske forstyrrelser, bevægelsesforstyrrelser, otorhinolaryngologiske forstyrrelser, gastrointestinale forstyrrelser, urogenitale forstyrrelser, dermatologiske forstyrrelser, smerteforstyrrelser, inflammatoriske forstyrrelser, sekretori-ske forstyrrelser, respiratoriske forstyrrelser, hypertrofiske forstyrrelser, arti-10 kulære forstyrrelser, endokrine forstyrrelser, autoimmune sygdomme, prolife- rativ sygdom, traumatiske læsioner og veterinære forstyrrelser.
10. Ikke-terapeutisk anvendelse af botulinumtoksin type A2 til behandling af kosmetiske forstyrrelser, der er valgt fra gruppen bestående af: 15 · huddefekter; • ansigtsasymmetri; • rynker, der er valgt blandt glabellapanderynker og ansigtsrynker; • nedadvendt mund; og • hårtab; 20 hvor anvendelsen omfatter administration af en virksom dosis botulinumtok sin type A2 til det område, hvor der er en kosmetisk forstyrrelse.
11. Anvendelse ifølge krav 10, hvor botulinumtoksinet type A2 er botulinum-neurotoksinkompleks type A2 eller botulinumneurotoksin type A2 med høj 25 renhed, og hvor botulinumtoksinet type A2 er en del af en fast eller flydende farmaceutisk sammensætning, der endvidere omfatter et overfladeaktivt stof.
12. Anvendelse ifølge krav 11, hvor den faste eller flydende farmaceutiske sammensætning endvidere omfatter en eller flere af de følgende bestandde- 30 le: • et krystallinsk stof, • en buffer til at holde en pH-værdi på mellem 5,5 og 7,5; • et disaccharid.
13. Anvendelse ifølge krav 12, hvor 3 • det overfladeaktive stof er valgt fra gruppen bestående af polysorbater med en gennemsnitlig polymeriseringsgrad i området fra 20 til 100 monomerenheder og poloxamere; • det krystallinske stof er natriumchlorid; 5 · bufferen bibeholder pH-værdien på mellem 5,8 og 7,0; • disaccharidet er valgt fra gruppen bestående af saccharose, trehalose, lak-tose og mannitol.
14. Anvendelse ifølge et af kravene 11 til 13, hvor det overfladeaktive stof er 10 polysorbat 80.
DK05767871.6T 2004-08-04 2005-08-03 Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2 DK1776137T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417367A GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin
GB0421290A GB2418359A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0421288A GB2418358A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0423952A GB2419526A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
GB0423953A GB2419527A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
PCT/GB2005/003036 WO2006013357A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2

Publications (1)

Publication Number Publication Date
DK1776137T3 true DK1776137T3 (da) 2015-01-05

Family

ID=35063257

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05767871.6T DK1776137T3 (da) 2004-08-04 2005-08-03 Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2
DK14180875.8T DK2813239T3 (da) 2004-08-04 2005-08-03 Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14180875.8T DK2813239T3 (da) 2004-08-04 2005-08-03 Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2

Country Status (9)

Country Link
US (2) US20080069841A1 (da)
EP (3) EP1776137B1 (da)
DK (2) DK1776137T3 (da)
ES (2) ES2627627T3 (da)
HU (1) HUE032950T2 (da)
PL (2) PL1776137T3 (da)
PT (2) PT1776137E (da)
TR (1) TR201708749T4 (da)
WO (1) WO2006013357A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
US9204925B2 (en) 2008-08-14 2015-12-08 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US8512715B2 (en) 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
CN102300584A (zh) 2008-12-31 2011-12-28 雷文斯治疗公司 可注射的肉毒杆菌毒素制剂
IL268980B (en) * 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
ES2643507T3 (es) * 2012-03-12 2017-11-23 William J. Binder Tratamiento de las cefaleas por migraña con la neurotoxina presináptica
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
BR112019004929A2 (pt) 2016-09-13 2019-06-04 Allergan Inc composições de toxina clostridial não proteíca
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
KR20220169510A (ko) * 2021-06-18 2022-12-28 충북대학교 산학협력단 불멸화 줄기세포의 엑소좀 풍부 배양액 및 보툴리눔 독소를 포함하는 기능성 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
AU743085B2 (en) * 1997-07-15 2002-01-17 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
ES2275992T5 (es) 2000-02-08 2011-05-18 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
GB2398636A (en) 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
EP1570855A1 (fr) * 2004-03-04 2005-09-07 Claude Le Louarn Utilisation de toxine botulique pour préparer un médicament destiné à prévenir la pousse de poils

Also Published As

Publication number Publication date
EP3210620A1 (en) 2017-08-30
DK2813239T3 (da) 2017-06-06
EP2813239A1 (en) 2014-12-17
EP2813239B1 (en) 2017-03-22
US20100184689A1 (en) 2010-07-22
PL2813239T3 (pl) 2017-11-30
ES2526912T3 (es) 2015-01-16
EP1776137A1 (en) 2007-04-25
EP1776137B1 (en) 2014-11-26
PL1776137T3 (pl) 2015-03-31
US20080069841A1 (en) 2008-03-20
TR201708749T4 (tr) 2018-03-21
PT2813239T (pt) 2017-06-09
HUE032950T2 (en) 2017-11-28
ES2627627T3 (es) 2017-07-28
WO2006013357A1 (en) 2006-02-09
PT1776137E (pt) 2014-12-31

Similar Documents

Publication Publication Date Title
DK1776137T3 (da) Farmaceutisk sammensætning indeholdende botulinumneurotoksin A2
EP1778279B1 (en) Pharmaceutical composition containing botulinum neurotoxin a2
US11534394B2 (en) Pharmaceutical composition containing botulinum neurotoxin
CN1316906A (zh) 稳定的肉毒毒素液体制剂
GB2419526A (en) Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) Pharmaceutical composition containing botulinum neurotoxin
GB2419527A (en) Pharmaceutical composition containing botulinum neurotoxin
GB2426702A (en) Pharmaceutical composition comprising botulinum neurotoxin
GB2418359A (en) Pharmaceutical composition comprising botulinum neurotoxin
GB2418358A (en) Pharmaceutical composition comprising botulinum neurotoxin